治疗皮肤状细胞癌的新辅助塞米普利马布疗法的有效性- 一个系统性审查
Maria Eduarda Palomba1, Julia Adriana Karmirski2, Flávio Carneiro Hojaij2
1Faculdade de Ciências Médicas da Santa Casa de São Paulo, FCMSCSP, Sao Paulo 01224-001, SP, Brazil.
International journal of molecular sciences
|August 28, 2025
概括
新辅助剂Cemiplimab在治疗皮肤状细胞癌 (cSCC) 中具有很高的疗效,改善了反应率和可控的副作用. 这种免疫疗法为晚期皮肤癌的传统治疗提供了有希望的替代方案.
科学领域:
- 癌症学
- 免疫疗法
- 皮肤病学
背景情况:
- 皮肤状细胞癌 (cSCC) 是一种常见的皮肤癌,通常用手术或化疗治疗,这可能导致变形和功能缺陷.
- 新兴的免疫治疗策略,特别是在新辅助的环境中,对先进的cSCC有希望.
- 作为一种PD-1抑制剂,Cemiplimab已在晚期cSCC中表现出有效性,并且正在作为新辅助疗法进行研究.
研究的目的:
- 评估Cemiplimab作为皮肤状细胞癌 (cSCC) 的新辅助疗法的疗效和安全性.
- 分析新辅助药Cemiplimab对cSCC患者的反应率,不良反应和整体治疗潜力.
主要方法:
- 根据PRISMA的指导方针进行了系统审查,分析了新辅助剂Cemiplimab对cSCC的研究.
- 搜索的数据库包括PubMed,科学网络和Scopus,包括受控试验,队列研究,病例系列和系统审查.
- 分析了包括21项研究的数据,其中6项临床试验提供了关键的疗效和安全数据.
主要成果:
- 新辅助剂Cemiplimab的平均病理反应率为72%,客观反应率为62%.
- 观察到完全病理反应 (cPR) 和主要病理反应 (mPR) 的高率.
- 与治疗相关的不良事件发生在66%的患者中,主要是轻微的,疲劳,皮疹和腹是最常见的.
结论:
- 新辅助药Cemiplimab治疗cSCC的反应率高,复发率低,并改善了可控副作用的生存率.
- 这种疗法即使在免疫抑制患者中也具有潜力,因此需要进一步研究.
- 新辅助剂Cemiplimab是对cSCC的有希望和有效的治疗选择,尽管仍需要长期数据和现实世界的证据.
更多相关视频
相关概念视频
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Renewal of Skin Epidermal Stem Cells
2.4K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.4K
Clinical Applications of Epidermal Stem Cells
2.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
Skin Diseases and Disorders
5.4K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.4K
Skin Cancer
5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


